By
Rajesh Gupta et al.
Published: July 18, 2015, 3:37 p.m.·
Tags:
Drug-resistant TB,
Treatment
New therapies are needed to address the imminent rise of drug-resistant infections. Delamanid is one of two new drugs approved for the treatment of multidrug-resistant tuberculosis (MDR-TB) in the past 40 years. The clinical evaluation of delamanid included a subgroup of patients with extensively drug-resistant tuberculosis (XDR-TB), which is more difficult to treat than MDR-TB. This evaluation provides an opportunity for a post hoc analysis of outcomes.
Read More →
